A Targeted Approach to Medicine and Dosing—A Necessity for Sustainable Healthcare

Maria Saluta

President Obama, during his 2015 State of the Union Address, launched the Precision Medicine Initiative “to enable a new era of medicine through research, technology, and policies that empower patients, researchers, and providers to work together toward development of individualized care.” The message given to the American people reinforced the critical need to implement precision medicine into […]

Read More
Topics: PBPK Modeling & Simulation

Quantitative Systems Toxicology

Integrating In Vitro and In Vivo Toxicity Data with Computational Modeling to Achieve a Pathway-based Approach to More Efficient Chemical Risk Assessment A major challenge in developing efficacious and safe drugs is the ability to understand and effectively predict adverse effects of xenobiotic substances on extremely complex biological systems early in the drug discovery process. […]

Read More
Topics:

Drug Development and Clinical Pharmacology Strategy

Changing the Game in Drug Development through a Strategic and Programmatic Approach Far too many cases treat drug development like a relay race, with the baton handed from one participant to the next. But, this approach risks missing opportunities to develop medicines faster and better. And lacking a holistic and strategic roadmap to achieve milestones […]

Read More
Topics:

The Model-informed Precision Dosing Revolution Is Coming

Suzanne Minton

Modeling and simulation (M&S) has been widely accepted and adopted by biopharmaceutical companies and global regulatory agencies. However, its implementation in clinical care has been modest to date. Model-based approaches are essential to realize the goal of precision dosing—providing the right drug dose to maximize therapeutic benefit, while reducing risk for each individual patient. The […]

Read More
Topics: PBPK Modeling & Simulation, PK/PD Modeling & Simulation

Orphan Drug Development

Orphan Drugs: Unique Challenges Require Unique Development Approaches Developing drugs for rare diseases poses a range of clinical, regulatory and commercial challenges. The small number of patient populations are difficult to identify and recruit for clinical trials. Many orphan diseases are genetic. Often these patients have complex phenotypes that react very differently to proposed treatment […]

Read More
Topics:

Benefits of Modeling and Simulation

The Benefits of Modeling and Simulation in Drug Development Biosimulation, also known as ‘modeling and simulation,’ or ‘model-based drug development,’ has already had a profound impact on drug development, yet its full impact is just now coming to light.  Modeling and simulation (M&S) has the proven ability to influence every phase of the drug development […]

Read More
Topics:

About Our Solutions

Cutting Edge Modeling and Simulation Solutions for Drug Development Drug development has become more complex and multi-layered.  New combination therapies require more precise and individualized analyses, new approaches such as “basket studies” evaluate potential disease targets through a new lens, safety issues are more challenging, and comparative effectiveness plays an increasingly important role in “go/no […]

Read More
Topics:

What You Need to Know about the Precision Medicine Initiative

Suzanne Minton

Last month, I was fortunate to be able to represent Certara at the BIO International Conference in Philadelphia, PA. One of the most exciting sessions that I attended was the Personalized Medicine Plenary with Dr. Francis Collins, the director of the NIH. He discussed how the Precision Medicine Initiative (PMI) will revolutionize the approach to […]

Read More
Topics: Clinical Transparency & Disclosure

Why Do We Customize Aminoglycoside Dosing?

Nathan Teuscher

Aminoglycosides are a class of molecules that are used for the treatment of serious gram-negative systemic infections. Some common aminoglycosides are tobramycin, gentamicin, amikacin, and neomycin. Aminoglycosides have bactericidal activity against most gram-negative bacteria including Acinetobacter, Citrobacter, Enterobacter, E. Coli, Klebsiella, Proteus, Providencia, Pseudomanas, Salmonella, Serratia and Shigella. Aminoglycosides are also active against most strains of Staphylococcus aureus and S. epidermidis. Most strains […]

Read More
Topics: PK/PD Modeling & Simulation

How Can PK/PD Analysis Add Value to Patient Care?

Nathan Teuscher

In May 2011, T.J. Smith and B.E. Hillner published an opinion piece in the New England Journal of Medicine titled “Bending the Cost Curve in Cancer Care” (link). In this opinion piece, Smith and Hillner suggest that the rapidly increasing cost of treating cancer is not sustainable. “We must find ways to reduce the costs […]

Read More
Topics: PK/PD Modeling & Simulation
Learn More LinkedIn Twitter Facebook Email Subscribe to the Blog